Pharma Stocks
-
Did Stevanato Group’s (STVN) German Manufacturing Expansion Just Shift Its Advanced Drug Delivery Investment Narrative?
Stevanato Group S.p.A. recently announced a significant expansion of its drug delivery system manufacturing capacity by adding over 2,500 square…
Read More » -
Strides Pharma shares rally 10% to hit all-time high; DAM Capital sees room for re-rating
Shares of Strides Pharma Ltd. surged 10% to a record high of ₹1,025 on Monday, November 3, extending gains for…
Read More » -
A Look at Amneal Pharmaceuticals (AMRX) Valuation After Robust Earnings and New FDA Respiratory Approval
Amneal Pharmaceuticals (AMRX) drew attention following a packed week of news. The company delivered higher sales and improved profitability last…
Read More » -
Royalty Pharma’s Major Royalty Deals and $2B Raise Could Be a Game Changer for RPRX
In the past week, Royalty Pharma announced it raised US$2.0 billion through senior unsecured notes and acquired royalties related to…
Read More » -
Phibro Animal Health Shares Surge 103% in 2025 Amid New Market Expansions
Ever wonder if Phibro Animal Health is actually a bargain right now? You are not alone. Many investors are examining…
Read More » -
Are these 3 pharma companies the market’s best-kept secret? Their numbers say yes. – Stock Insights News
The Indian pharmaceutical industry has always played a pivotal role in the global healthcare industry. While India has always been…
Read More » -
Evaluating BridgeBio Pharma After 122% Rally and Clinical Trial Breakthroughs
Wondering if BridgeBio Pharma is now a bargain or still too risky? You’re not alone. Let’s dig into what the…
Read More » -
Is Axsome Therapeutics Set for More Gains After Promising Clinical Trial News in 2025?
Wondering if Axsome Therapeutics is a smart buy right now? You’re not alone, as plenty of investors are asking what…
Read More » -
Does Merck KGaA’s 19% Drop Signal Opportunity Amid Changing Pharma Landscape?
Wondering if Merck KGaA’s recent price dip is actually presenting a hidden value opportunity? You’re not alone. Knowing how to…
Read More » -
Hanall Biopharma’s (KRX:009420) 43% CAGR outpaced the company’s earnings growth over the same three-year period
It might seem bad, but the worst that can happen when you buy a stock (without leverage) is that its…
Read More »